Skip to main content

Posts

Showing posts with the label Glioblastoma Multiforme

GAELs for GBM Treatment

 Can Glycosylated Antitumor Ether Lipid be used to treat GBM? ChatGPT said: Great question. Let's break it down clearly and carefully. Glycosylated Antitumor Ether Lipids (GAELs) are a class of synthetic lipid-based molecules designed to have anticancer properties. They are derivatives of antitumor ether lipids (AELs) , with added sugar moieties (glycosylation) to improve selectivity, solubility, and reduce toxicity. Use of GAELs in GBM (Glioblastoma Multiforme): 1. Research Evidence: Direct studies on GAELs and GBM are limited. There is preclinical evidence that antitumor ether lipids (especially compounds like edelfosine or miltefosine ) have activity against glioblastoma cells in vitro . Glycosylated variants of these compounds (GAELs) have shown antitumor activity in other cancers, such as leukemia, melanoma, and breast cancer, but direct clinical studies on GBM are sparse or non-existent as of now (2024). 2. Mechanism of Action: GAELs are thought to: D...

When GBM Entered Our Lives

When Christina was diagnosed with Glioblastoma (GBM) in February 2020, our world flipped upside down. The idea of losing my wife to cancer became a terrifying reality. Emotions were chaotic, and thinking clearly felt impossible. Our first instinct was to learn everything we could about this disease. Information came at us fast and from every direction. The most shocking fact? GBM is the most common primary malignant brain tumor in adults, with a median survival of only 15 months (1). Treatment usually begins with a biopsy and tumor removal , followed by radiotherapy and chemotherapy with alkylating agents . Christina received temozolomide (TMZ) , and later bevacizumab , a monoclonal antibody that blocks the tumor’s blood supply (10). I’ve decided to write a series of posts documenting what I’ve learned about GBM and my ideas—naïve though they may be—about how we might improve outcomes for patients, from the perspective of a chemist. During my chemistry career (1984–1998), I worked on ...